Actively Recruiting
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Led by Kumquat Biosciences Inc. · Updated on 2026-04-17
46
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.
CONDITIONS
Official Title
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have unresectable or metastatic gastrointestinal stromal tumor (GIST)
- Tissue confirmation of GIST diagnosis
- Valid local test results showing KIT mutation (excluding exon 9) or PDGFRA mutation (excluding PDGFRA D842V)
- Measurable disease according to RECIST v1.1 criteria
- Currently in first-line treatment for advanced or metastatic disease; prior imatinib allowed if stopped over 1 year ago
- Adequate organ function and performance status
You will not qualify if you...
- Unable to swallow or have gastrointestinal conditions preventing drug absorption
- Have had other active cancers within the last 2 years
- History of allergic reaction to any part of KQB198 or imatinib
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
Research Team
K
Kumquat Clinical Development
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here